c-LEcta introduces a new GMP Cell Dissociation Enzyme for Biopharmaceutical Manufacturing
c-LEcta, a Kerry company, announces the launch of CellTrypase, a new recombinant trypsin-like enzyme of fungal origin, that was especially developed for biopharmaceutical customers looking for the highest quality and supply chain standards for raw materials.
Trypsin-like enzymes such as CellTrypase can be used for the gentle and efficient dissociation of cells in GMP-compliant bioprocessing and R&D workflows. Typical GMP cell culture applications include the production of viral vectors for cell & gene therapies, vaccine manufacturing, stem cell processing, tissue engineering and cell banking. CellTrypase is validated across key biopharma production cell lines and can be used as a direct replacement for animal-derived or recombinant trypsin solutions in existing workflows. Manufacturers can incorporate the enzyme into existing processes without requiring extensive process revalidation or further optimization.
GMP-compliant production with full traceability
CellTrypase is manufactured in our brand new GMP-certified production facility in Leipzig Germany, ensuring full traceability and adherence to GMP/GDP requirements. Complete batch traceability is maintained from acquisition of raw materials to final release, offering transparency for manufacturers and regulatory bodies.
Highest purity
The proprietary production process features gentle manufacturing steps, ensuring the integrity of the product throughout the process. The result is a highly active enzyme solution. ≥95% purity is specified as a release-relevant parameter, providing consistent performance in sensitive cell culture applications.
CellTrypase is produced through microbial fermentation using a Bacillus species. The manufacturing process is free of animal derived materials. The product is supplied as a ready-to-use, sterile filtered liquid enzyme and integrates seamlessly into standard cell culture workflows. CellTrypase is stable at 2–8 °C and can be shipped at ambient temperature, facilitating storage and logistics. Various formats and packaging sizes are available, accommodating needs from small-scale development to bulk biopharmaceutical GMP manufacturing.
In summary, CellTrypase addresses a growing demand of the biopharmaceutical industry for consistent, safe and traceable bioprocessing materials, with a focus on innovative modalities such as cell and gene therapies.
About Kerry Biotechnology Centre, powered by c-LEcta
CellTrypase is the first new enzyme product launched at the recently opened Kerry Biotechnology Centre. c-LEcta, the operator of the Biotechnology Centre, has over 20 years of experience in the field of enzyme development and manufacturing and joined Kerry group in 2022. World-class enzyme engineering and production technologies are used to provide the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. The Kerry Biotechnology Centre employs more than 130 people and supplies products to more than 400 customers in over 40 countries.
The Kerry Biotechnology Centre brings together the full biotechnology journey – from enzyme discovery and strain engineering to process development and production – all under one roof. 80+ scientists and innovation experts are focused on driving the discovery of next-generation solutions.